In this respect, one of the interesting genes identified as differentially expressed between high CD8+ TIL and low CD8+ TIL tumours and associated with DSS of late-stage serous ovarian cancer patients is interferon regulatory factor 1 (IRF-1). This evidence concerns the gene IRF1 and neoplasm.